Q/C Technologies, Inc. Derivative Liability, Noncurrent
Q/C Technologies, Inc. (QCLS) had Derivative Liability, Noncurrent of $3.46 million as of 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2023-08-14
- 2023-06-30: Derivative Liability, Noncurrent $3.46M.
- 2023-03-31: Derivative Liability, Noncurrent $3.27M.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2023-06-30 | $3.46M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $3.27M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |